A self-taught snake expert's 200 snake bites may lead to a universal ‘cure' for snake venom
Sure, troops getting bitten and envenomated by poisonous snakes isn't high on the list of things the Department of Defense needs to worry about. It's probably not even in the top 100, but for the guy in the unit who was bitten by a Saw-Scaled Viper while out on patrol. That particular viper is active at night, very common in Afghanistan, and is responsible for the most deaths by snake bite. It would take about 15 minutes to become one of the biggest issues a troop has out in the field.
But to combat a venomous snake bite, you need to get the specific snake's antivenin, if one is available. Getting a specific kind of snake antivenin anywhere in Afghanistan was a logistical nightmare, not to mention that the U.S. military had to acquire the treatment from the government of Iran – who has not traditionally been our best friend.
It would be so much easier if your medic or doc just happened to have that kind of treatment readily available, but since there are more than 100 different kinds of snake antivenins available, the chances aren't great. In America's next war, however, things might be different. A former truck driver from California has been on a nearly 20-year journey of injecting himself with snake venom and his effort may have led to a universal cure for venomous snakebites.
Tim Friede is a self-taught herpetologist, a scientist from an old breed. He's like Evan O'Neill Kane, who removed his own appendix to prove it could be done using local anaesthetic, or Dr. Barry Marshall, who ate a dish of H. pylori bacteria to prove it caused ulcers. He's a researcher at Centivax, a biotech firm with the mission of creating universal vaccines and broad spectrum anti-infectives. While the company is working with the Department of Defense to create new antibiotics and a universal vaccine for influenza, Friede is on a whole different project.
Friede's project is a broad-spectrum anti-venom, but his methods are pretty unusual. He started out by injecting himself with snake venom to build up an immunity, in case he was bitten while handling snakes at work. When he received two cobra bites in a row that left him in a coma, he decided to take a different approach. He has since taken more than 200 bites and more than 700 injections of venom, many from the world's deadliest snakes with venom that can kill a human very quickly – unless that human is Tim Friede.
The way antivenin (or anti-venom) serums are created is by injecting small amounts of the poison into animals like horses or lambs. When the animals' immune systems start producing antibodies to fight the intruder, the antibodies are harvested and made into life-saving treatments. The only problem is, historically, you need to know what bit you. The snake anti-venom serum has to be matched to the snake. Centivax, with its unique mission, started looking to create something more universal. That's where Friede came in.
If the cobra that put Friede in a coma were to bite him today, the only effect it would have is a slightly annoyed Tim Friede. He's not only immune to cobras, he's been bitten by mambas, kraits and even taipans, the world's most toxic snake.
'It just became a lifestyle and I just kept pushing and pushing and pushing as hard as I could push,' Friede told the BBC. '… for the people who are 8,000 miles away from me who die from snakebite.'
Centivax began looking for antibodies from 19 elapids, snakes whose venom is a potent neurotoxin in Friede's blood. The ones they chose are identified by the World Health Organization as among the world's deadliest. They found them. A study published in the medical journal 'Cell' revealed two 'broadly neutralizing antibodies' that protected lab mice from fatal doses from 13 of 19 venomous snake species. That kind of protection means it can cover venomous bites from some snakes that don't currently have an antivenin and may even lead to a treatment for all elapid bites.
There are currently a dozen different classes of toxins within snake venoms, and because of Tim Friede's 20-year mission, there may soon be a 'cure' for all of them within the next 20 years.
'I'm doing something good for humanity and that was very important to me,' he said. 'I'm proud of it. It's pretty cool.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Space photo of the day for June 19, 2025
When you buy through links on our articles, Future and its syndication partners may earn a commission. With the upcoming Artemis 2 mission slated for launch in April 2026, the crew members practice all scenarios, including the worst cases. Crew members assigned to the Artemis 2 mission practice with mannequins inside the Crew Module Test Article (CMTA), a full-scale mockup of the Orion spacecraft, as it falls into Floridian waters as a part of a recovery procedure for a launch pad abort scenario. The module was recovered off the coast of Florida near the agency's Kennedy Space Center. The Artemis 2 mission is part of a decades long legacy in NASA's attempts to return to the moon. It will be the "first crewed mission on NASA's path to establishing a long-term presence at the moon, according to NASA. Building on the work of the Artemis 1 mission, which launched in 2022, Artemis 2 will send four crew members aboard the Orion spacecraft around the moon for 10 days. During this time the crew will be able to test the spacecraft to all the systems operate to keep humans alive in the deep space environment. Unfortunately, there are many things that can happen to stop the launch from happening, and the crew needs to be prepared for all scenarios. Working with the Department of Defense, along with NASA's flight control teams, the Artemis 2 crew members rehearse a launch pad abort scenario, using mannequins. While the mission is still several months away, running through all emergency procedures allows the team to be as prepared as possible for launch day. You can read more about the Artemis 2 mission and returning to the moon as the project's launch date gets closer.
Yahoo
4 days ago
- Yahoo
Is Increased Focus on Hypersonic Tech Opening New Doors for Rocket Lab?
In recent years, the rapid development and adoption of hypersonic technology across industries, from aerospace and defense to space exploration, have opened new growth avenues for Rocket Lab USA RKLB, a key player in hypersonic testing with its HASTE launch system. With commercial firms and government agencies ramping up investments in advanced hypersonic systems to bolster space access and national security, RKLB remains well-positioned to capitalize on this accelerating technological shift. Notably, Rocket Lab's HAEST (Hypersonic accelerator suborbital test electron) is a suborbital testbed launch vehicle that provides reliable, high-cadence flight test opportunities needed to boost hypersonic and suborbital system technology development. In April 2025, Rocket Lab secured a contract from Kratos Defense to conduct a full-scale hypersonic test flight for the U.S. Department of Defense. Additionally, RKLB's HASTE platform has been included in two major defense frameworks — the $46 billion Enterprise-Wide Agile Acquisition Contract with the U.S. Air Force and the UK Ministry of Defence's £1 billion ($1.3 billion) Hypersonic Technologies & Capability Development Framework. These programs allow Rocket Lab to compete for launch and engineering services in advancing hypersonic technologies. The inclusion across both U.S. and UK initiatives underscores the growing demand for HASTE in defense testing and is likely to significantly boost Rocket Lab's future revenue stream. While HASTE has not yet won any purely commercial contract, its demonstrated reliability and cadence in the defense sector may soon open doors to non-defense payload opportunities. As increased investment in hypersonic technology has become a global trend lately, with nations like the United States, the United Kingdom, and China significantly boosting funding for research and development in this tech, other stocks like Lockheed Martin LMT and RTX Corp. RTX are also indulging in advanced hypersonic technology developments. Notably, Lockheed Martin has been developing highly advanced hypersonic technology for the past 60 years. To this end, the company is currently working in partnership with DARPA, the U.S. Air Force, the U.S. Army, and the U.S. Navy to transition hypersonic concepts to operational reality. LMT's Conventional Prompt Strike is a hypersonic boost-glide missile currently under development, which boasts the capability to provide longer range, shorter flight times, and high survivability against enemy defenses. On the other hand, RTX is working across its business and domains to move advanced hypersonic capabilities from creation to testing and into the hands of warfighters at top speed. RTX is currently involved in the design of the Hypersonic Attack Cruise Missile, which leverages Northrop Grumman's scramjet propulsion to travel at more than five times the speed of sound and cover vast distances in minutes. The U.S. Air Force currently expects this missile to be operational by fiscal 2027. Shares of RKLB have surged 467.2% in the past year compared with the industry's 40.9% growth. Image Source: Zacks Investment Research The company's shares are trading at a premium on a relative basis, with its forward 12-month Price/Sales being 17.85X compared with its industry's average of 9.65X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for RKLB's 2025 and 2026 earnings has improved over the past 60 days. Image Source: Zacks Investment Research RKLB currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report RTX Corporation (RTX) : Free Stock Analysis Report Rocket Lab Corporation (RKLB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
New York Times
5 days ago
- New York Times
Kennedy's Purge Is a ‘Code Red' for Vaccines in America
'Some people believe that the term anti-vaxxer is a pejorative,' the physician Robert Malone wrote on June 9. 'I do not — I view it as high praise.' Early in the pandemic, Malone campaigned for treatment with ivermectin and hydroxychloroquine and against mRNA vaccines, which he described as 'causing a form of' AIDS, though he later admitted he received the Moderna vaccine to treat his own long Covid. In 2021, Malone circulated a 2013 video of a high school athlete collapsing on the football field, blaming coronavirus vaccination for the death before he was served with a cease-and-desist letter from the family. More recently, he dismissed as 'misinformation' news reports attributing the deaths of two girls in Texas to measles, blaming not vaccine refusal but 'medical errors,' and last fall published a book, 'PsyWar,' claiming that between the C.I.A. and Department of Defense, the United States maintains 'reality-bending information control capabilities' and that much of federal government's business is conducted via sexual favor. 'The term 'anti-vaxxer,'' he repeated June 9, 'it is not a slur, but a compliment.' Two days later, he was appointed to the advisory board that steers America's vaccine policy. Richard Nixon conducted his 'Saturday night massacre,' back in 1973, when one after another federal prosecutor refused to withdraw a subpoena of the White House tapes. Robert F. Kennedy Jr., the health and human services secretary, staged his night of the long knives a week ago Monday, firing all 17 members of the vaccine advisory board, called the A.C.I.P., in one fell swoop — a historically unprecedented action and one that broke an explicit promise he made to Senator Bill Cassidy, Republican of Louisiana and a physician, as a condition of his confirmation as secretary. The epidemiologist and immunologist Michael Mina called Kennedy's move a 'code red' for vaccines in America. None of the A.C.I.P. advisers were warned or had their firings explained; they had to read the news in a Wall Street Journal op-ed that accused them of 'malevolent malpractice.' Cassidy, who dodged questions from reporters on the subject, was left sputtering on X: 'Of course, now the fear is that the A.C.I.P. will be filled up with people who know nothing about vaccines except suspicion.' Malone, whose appointment to the board hadn't yet been announced, posted proudly, 'Promises made, promises kept.' The new appointees are not all fully committed skeptics — though, beyond Malone, they include several people who have testified in lawsuits against vaccine manufacturers, as well as a longstanding board member for an anti-vaccine nonprofit and an M.I.T. business-school professor who has been publicly describing mRNA vaccines as mass killers since 2023. (The choices also include a nutritional scientist focused on fatty acids in the brain and a founder of a biotech company without a single piece of published research to his name.) The new group fails to include experts on any diseases that vaccines prevent. Or experts on vaccines themselves. Or experts on infectious-disease epidemiology. Or experts on clinical trials. 'We've taken people who had expertise and fired them for a bogus reason,' says the University of Pennsylvania vaccinologist Paul Offit, a former member of the A.C.I.P. and the creator of the rotavirus vaccine. In their place have been installed what the bioethicist Ezekiel Emanuel, also of the University of Pennsylvania, described to me as 'vaccine skeptics.' Offit calls them, more pointedly, 'purveyors of disinformation.' Want all of The Times? Subscribe.
